Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making.

IF 3 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2026-09-23 DOI:10.1080/14737140.2026.2722166

Sikander Ailawadhi, Swetha Challagulla, Yan Meng, Todor I Totev, Dominic Pilon, Lilian Diaz, Zhuo Chen, Keri Yang

{"title":"Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making.","authors":"Sikander Ailawadhi, Swetha Challagulla, Yan Meng, Todor I Totev, Dominic Pilon, Lilian Diaz, Zhuo Chen, Keri Yang","doi":"10.1080/14737140.2026.2722166","DOIUrl":null,"url":null,"abstract":"Background: Chronic lymphocytic leukemia (CLL) treatment attributes can impact patient treatment preferences.Research design and methods: A discrete choice experiment survey was conducted among adults with CLL from the United States (12/2024-02/2025). Treatment attributes, selected via literature review and clinical input, spanned across efficacy, safety, and convenience (continuous vs fixed duration with monitoring/hospitalization requirements). Attributes' relative importance was calculated using conditional logistic regression.Results: Among 199 patients with CLL, attributes with the highest relative importance were progression-free survival (PFS; 29.5%), impact of headache, atrial fibrillation, and kidney dysfunction on quality of life (QoL; 25.9%, 24.4%, and 10.1%, respectively), followed by treatment convenience (5.4%) and impacts of diarrhea (3.5%) and hypertension (1.1%) on QoL. Patients preferred treatments with longer PFS and less impact of headache, atrial fibrillation, and kidney dysfunction on QoL (p < 0.001). Impacts of diarrhea and hypertension on QoL and treatment convenience had no statistically significant influence on treatment preferences.Conclusions: PFS, impacts of headache, and atrial fibrillation on QoL were the most important treatment attributes for patients with CLL, whereas treatment convenience did not have a statistically significant impact on patient preferences. CLL treatment discussions should incorporate safety alongside efficacy to support patient-centered care.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":3.0000,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2026.2722166","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic lymphocytic leukemia (CLL) treatment attributes can impact patient treatment preferences.

Research design and methods: A discrete choice experiment survey was conducted among adults with CLL from the United States (12/2024-02/2025). Treatment attributes, selected via literature review and clinical input, spanned across efficacy, safety, and convenience (continuous vs fixed duration with monitoring/hospitalization requirements). Attributes' relative importance was calculated using conditional logistic regression.

Results: Among 199 patients with CLL, attributes with the highest relative importance were progression-free survival (PFS; 29.5%), impact of headache, atrial fibrillation, and kidney dysfunction on quality of life (QoL; 25.9%, 24.4%, and 10.1%, respectively), followed by treatment convenience (5.4%) and impacts of diarrhea (3.5%) and hypertension (1.1%) on QoL. Patients preferred treatments with longer PFS and less impact of headache, atrial fibrillation, and kidney dysfunction on QoL (p < 0.001). Impacts of diarrhea and hypertension on QoL and treatment convenience had no statistically significant influence on treatment preferences.

Conclusions: PFS, impacts of headache, and atrial fibrillation on QoL were the most important treatment attributes for patients with CLL, whereas treatment convenience did not have a statistically significant impact on patient preferences. CLL treatment discussions should incorporate safety alongside efficacy to support patient-centered care.

查看原文本刊更多论文

慢性淋巴细胞白血病（CLL）治疗属性影响患者共同决策的前瞻性患者偏好研究。

背景：慢性淋巴细胞白血病（CLL）的治疗属性会影响患者的治疗偏好。研究设计与方法：对美国成年CLL患者（2024年12月- 2025年2月）进行离散选择实验调查。通过文献回顾和临床输入选择治疗属性，涵盖疗效、安全性和便利性（连续vs固定持续时间，并有监测/住院要求）。使用条件逻辑回归计算属性的相对重要性。结果：199例CLL患者中，相对重要性最高的属性是无进展生存期（PFS, 29.5%）、头痛、心房颤动和肾功能障碍对生活质量的影响（QoL，分别为25.9%、24.4%和10.1%），其次是治疗便利性（5.4%）、腹泻（3.5%）和高血压（1.1%）对生活质量的影响。患者首选PFS较长、头痛、房颤和肾功能不全对生活质量影响较小的治疗方法(p)。结论：PFS、头痛和房颤对生活质量的影响是CLL患者最重要的治疗属性，而治疗便利性对患者偏好的影响无统计学意义。CLL治疗讨论应包括安全性和有效性，以支持以患者为中心的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.